journal

Lancet Neurology

journal
https://read.qxmd.com/read/31706889/antihypertensive-medications-and-risk-for-incident-dementia-and-alzheimer-s-disease-a-meta-analysis-of-individual-participant-data-from-prospective-cohort-studies
#1
Jie Ding, Kendra L Davis-Plourde, Sanaz Sedaghat, Phillip J Tully, Wanmei Wang, Caroline Phillips, Matthew P Pase, Jayandra J Himali, B Gwen Windham, Michael Griswold, Rebecca Gottesman, Thomas H Mosley, Lon White, Vilmundur Guðnason, Stéphanie Debette, Alexa S Beiser, Sudha Seshadri, M Arfan Ikram, Osorio Meirelles, Christophe Tzourio, Lenore J Launer
BACKGROUND: Dementia is a major health concern for which prevention and treatment strategies remain elusive. Lowering high blood pressure with specific antihypertensive medications (AHMs) could reduce the burden of disease. We investigated whether specific AHM classes reduced the risk for dementia. METHODS: We did a meta-analysis of individual participant data from eligible observational studies published between Jan 1, 1980, and Jan 1, 2019. Cohorts were eligible for inclusion if they prospectively recruited community-dwelling adults; included more than 2000 participants; collected data for dementia events over at least 5 years; had measured blood pressure and verified use of AHMs; included in-person exams, supplemented with additional data, to capture dementia events; and had followed up cases for mortality...
November 6, 2019: Lancet Neurology
https://read.qxmd.com/read/31706888/advancing-dementia-prevention-through-effective-blood-pressure-control
#2
Ruth Peters, Craig S Anderson
No abstract text is available yet for this article.
November 6, 2019: Lancet Neurology
https://read.qxmd.com/read/31678033/increased-striatal-dopamine-in-carriers-of-gba-mutations-compensation-or-epiphenomenon
#3
Nicolaas I Bohnen, Roger L Albin
No abstract text is available yet for this article.
October 30, 2019: Lancet Neurology
https://read.qxmd.com/read/31678032/clinical-and-dopamine-transporter-imaging-characteristics-of-non-manifest-lrrk2-and-gba-mutation-carriers-in-the-parkinson-s-progression-markers-initiative-ppmi-a-cross-sectional-study
#4
Tanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, Chelsea Caspell-Garcia, Christopher S Coffey, Andrew Siderowf, John Q Trojanowski, Leslie M Shaw, John Seibyl, Andrew Singleton, Arthur W Toga, Doug Galasko, Tatiana Foroud, Duygu Tosun, Kathleen Poston, Daniel Weintraub, Brit Mollenhauer, Caroline M Tanner, Karl Kieburtz, Lana M Chahine, Alyssa Reimer, Samantha J Hutten, Susan Bressman, Kenneth Marek
BACKGROUND: The Parkinson's Progression Markers Initiative (PPMI) is an ongoing observational, longitudinal cohort study of participants with Parkinson's disease, healthy controls, and carriers of the most common Parkinson's disease-related genetic mutations, which aims to define biomarkers of Parkinson's disease diagnosis and progression. All participants are assessed annually with a battery of motor and non-motor scales, 123-I Ioflupane dopamine transporter (DAT) imaging, and biological variables...
October 30, 2019: Lancet Neurology
https://read.qxmd.com/read/31628009/glycolysis-as-a-therapeutic-target-for-parkinson-s-disease
#5
Thomas Foltynie
No abstract text is available yet for this article.
October 15, 2019: Lancet Neurology
https://read.qxmd.com/read/31587955/an-exoskeleton-controlled-by-an-epidural-wireless-brain-machine-interface-in-a-tetraplegic-patient-a-proof-of-concept-demonstration
#6
Alim Louis Benabid, Thomas Costecalde, Andrey Eliseyev, Guillaume Charvet, Alexandre Verney, Serpil Karakas, Michael Foerster, Aurélien Lambert, Boris Morinière, Neil Abroug, Marie-Caroline Schaeffer, Alexandre Moly, Fabien Sauter-Starace, David Ratel, Cecile Moro, Napoleon Torres-Martinez, Lilia Langar, Manuela Oddoux, Mircea Polosan, Stephane Pezzani, Vincent Auboiroux, Tetiana Aksenova, Corinne Mestais, Stephan Chabardes
BACKGROUND: Approximately 20% of traumatic cervical spinal cord injuries result in tetraplegia. Neuroprosthetics are being developed to manage this condition and thus improve the lives of patients. We aimed to test the feasibility of a semi-invasive technique that uses brain signals to drive an exoskeleton. METHODS: We recruited two participants at Clinatec research centre, associated with Grenoble University Hospital, Grenoble, France, into our ongoing clinical trial...
October 3, 2019: Lancet Neurology
https://read.qxmd.com/read/31587954/is-a-four-limb-exoskeleton-a-step-in-the-wrong-direction
#7
Tom Shakespeare
No abstract text is available yet for this article.
October 3, 2019: Lancet Neurology
https://read.qxmd.com/read/31526626/the-dawn-of-robust-individualised-risk-models-for-dementia
#8
Samantha C Burnham, Samantha M Loi, James Doecke, Victor Fedyashov, Vincent Dore, Victor L Villemagne, Colin L Masters
No abstract text is available yet for this article.
September 13, 2019: Lancet Neurology
https://read.qxmd.com/read/31526625/biomarker-based-prognosis-for-people-with-mild-cognitive-impairment-abide-a-modelling-study
#9
Ingrid S van Maurik, Stephanie J Vos, Isabelle Bos, Femke H Bouwman, Charlotte E Teunissen, Philip Scheltens, Frederik Barkhof, Lutz Frolich, Johannes Kornhuber, Jens Wiltfang, Wolfgang Maier, Oliver Peters, Eckart Rüther, Flavio Nobili, Giovanni B Frisoni, Luiza Spiru, Yvonne Freund-Levi, Asa K Wallin, Harald Hampel, Hilkka Soininen, Magda Tsolaki, Frans Verhey, Iwona Kłoszewska, Patrizia Mecocci, Bruno Vellas, Simon Lovestone, Samantha Galluzzi, Sanna-Kaisa Herukka, Isabel Santana, Ines Baldeiras, Alexandre de Mendonça, Dina Silva, Gael Chetelat, Stephanie Egret, Sebastian Palmqvist, Oskar Hansson, Pieter Jelle Visser, Johannes Berkhof, Wiesje M van der Flier
BACKGROUND: Biomarker-based risk predictions of dementia in people with mild cognitive impairment are highly relevant for care planning and to select patients for treatment when disease-modifying drugs become available. We aimed to establish robust prediction models of disease progression in people at risk of dementia. METHODS: In this modelling study, we included people with mild cognitive impairment (MCI) from single-centre and multicentre cohorts in Europe and North America: the European Medical Information Framework for Alzheimer's Disease (EMIF-AD; n=883), Alzheimer's Disease Neuroimaging Initiative (ADNI; n=829), Amsterdam Dementia Cohort (ADC; n=666), and the Swedish BioFINDER study (n=233)...
September 13, 2019: Lancet Neurology
https://read.qxmd.com/read/31521533/the-genetic-architecture-of-parkinson-s-disease
#10
REVIEW
Cornelis Blauwendraat, Mike A Nalls, Andrew B Singleton
Parkinson's disease is a complex neurodegenerative disorder for which both rare and common genetic variants contribute to disease risk, onset, and progression. Mutations in more than 20 genes have been associated with the disease, most of which are highly penetrant and often cause early onset or atypical symptoms. Although our understanding of the genetic basis of Parkinson's disease has advanced considerably, much remains to be done. Further disease-related common genetic variability remains to be identified and the work in identifying rare risk alleles has only just begun...
September 11, 2019: Lancet Neurology
https://read.qxmd.com/read/31521532/effectiveness-of-home-based-and-remotely-supervised-aerobic-exercise-in-parkinson-s-disease-a-double-blind-randomised-controlled-trial
#11
Nicolien M van der Kolk, Nienke M de Vries, Roy P C Kessels, Hilde Joosten, Aeilko H Zwinderman, Bart Post, Bastiaan R Bloem
BACKGROUND: High-intensity aerobic exercise might attenuate the symptoms of Parkinson's disease, but high-quality evidence is scarce. Moreover, long-term adherence remains challenging. We aimed to evaluate the effectiveness of aerobic exercise-gamified and delivered at home, to promote adherence-on relieving motor symptoms in patients with Parkinson's disease with mild disease severity who were on common treatment regimes. METHODS: In this single-centre, double-blind, randomised controlled trial (Park-in-Shape), we recruited sedentary patients with Parkinson's disease from the outpatient clinic at Radboudumc, Nijmegen, Netherlands...
September 11, 2019: Lancet Neurology
https://read.qxmd.com/read/31519472/new-evidence-on-the-management-of-lewy-body-dementia
#12
REVIEW
John-Paul Taylor, Ian G McKeith, David J Burn, Brad F Boeve, Daniel Weintraub, Claire Bamford, Louise M Allan, Alan J Thomas, John T O'Brien
Dementia with Lewy bodies and Parkinson's disease dementia, jointly known as Lewy body dementia, are common neurodegenerative conditions. Patients with Lewy body dementia present with a wide range of cognitive, neuropsychiatric, sleep, motor, and autonomic symptoms. Presentation varies between patients and can vary over time within an individual. Treatments can address one symptom but worsen another, which makes disease management difficult. Symptoms are often managed in isolation and by different specialists, which makes high-quality care difficult to accomplish...
September 10, 2019: Lancet Neurology
https://read.qxmd.com/read/31501026/anne-cross-it-s-a-family-affair
#13
Adrian Burton
No abstract text is available yet for this article.
September 6, 2019: Lancet Neurology
https://read.qxmd.com/read/31494011/epilepsy-genetics-clinical-impacts-and-biological-insights
#14
REVIEW
Colin A Ellis, Slavé Petrovski, Samuel F Berkovic
Genomics now has an increasingly important role in neurology clinics. Regarding the epilepsies, innovations centred around technology, analytics, and collaboration have led to remarkable progress in gene discovery and have revealed the diverse array of genetic mechanisms and neurobiological pathways that contribute to these disorders. The new genomic era can present a challenge to clinicians, who now find themselves asked to interpret and apply genetic data to their daily management of patients with epilepsy...
September 4, 2019: Lancet Neurology
https://read.qxmd.com/read/31494010/epilepsy-genetics-and-the-precision-medicine-matrix
#15
Sanjay M Sisodiya
No abstract text is available yet for this article.
September 4, 2019: Lancet Neurology
https://read.qxmd.com/read/31494009/dementia-in-china-epidemiology-clinical-management-and-research-advances
#16
REVIEW
Longfei Jia, Meina Quan, Yue Fu, Tan Zhao, Yan Li, Cuibai Wei, Yi Tang, Qi Qin, Fen Wang, Yuchen Qiao, Shengliang Shi, Yan-Jiang Wang, Yifeng Du, Jiewen Zhang, Junjian Zhang, Benyan Luo, Qiumin Qu, Chunkui Zhou, Serge Gauthier, Jianping Jia
China has the largest population of patients with dementia in the world, imposing a heavy burden on the public and health care systems. More than 100 epidemiological studies on dementia have been done in China, but the estimates of the prevalence and incidence remain inconsistent because of the use of different sampling methods. Despite improved access to health services, inadequate diagnosis and management for dementia is still common, particularly in rural areas. The Chinese Government issued a new policy to increase care facilities for citizens older than 65 years, but most patients with dementia still receive care at home...
September 4, 2019: Lancet Neurology
https://read.qxmd.com/read/31492653/another-sphingosine-1-phosphate-receptor-modulator-for-the-treatment-of-patients-with-multiple-sclerosis
#17
Ellen M Mowry, John R Corboy
No abstract text is available yet for this article.
September 3, 2019: Lancet Neurology
https://read.qxmd.com/read/31492652/safety-and-efficacy-of-ozanimod-versus-interferon-beta-1a-in-relapsing-multiple-sclerosis-radiance-a-multicentre-randomised-24-month-phase-3-trial
#18
Jeffrey A Cohen, Giancarlo Comi, Krzysztof W Selmaj, Amit Bar-Or, Douglas L Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Kubala Havrdová, Bruce A C Cree, James K Sheffield, Neil Minton, Kartik Raghupathi, Vivian Huang, Ludwig Kappos
BACKGROUND: Ozanimod is a sphingosine 1-phosphate receptor modulator, which selectively binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity. In the RADIANCE phase 2 study in participants with relapsing multiple sclerosis, ozanimod was associated with better efficacy than placebo on MRI measures and was well tolerated. The RADIANCE phase 3 study aimed to confirm the safety and efficacy of ozanimod versus interferon beta-1a in individuals with relapsing multiple sclerosis...
September 3, 2019: Lancet Neurology
https://read.qxmd.com/read/31492651/safety-and-efficacy-of-ozanimod-versus-interferon-beta-1a-in-relapsing-multiple-sclerosis-sunbeam-a-multicentre-randomised-minimum-12-month-phase-3-trial
#19
Giancarlo Comi, Ludwig Kappos, Krzysztof W Selmaj, Amit Bar-Or, Douglas L Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Kubala Havrdová, Bruce A C Cree, James K Sheffield, Neil Minton, Kartik Raghupathi, Ning Ding, Jeffrey A Cohen
BACKGROUND: Ozanimod, a sphingosine 1-phosphate receptor modulator, selectively binds to receptor subtypes 1 and 5 with high affinity. The RADIANCE phase 2 study showed that ozanimod had better efficacy than placebo on MRI measures, with a favourable safety profile, in participants with relapsing multiple sclerosis. The SUNBEAM study aimed to assess the safety and efficacy of ozanimod versus intramuscular interferon beta-1a in participants with relapsing multiple sclerosis. METHODS: SUNBEAM was a randomised, double-blind, double-dummy, active-controlled phase 3 trial done at 152 academic medical centres and clinical practices in 20 countries...
September 3, 2019: Lancet Neurology
https://read.qxmd.com/read/31451408/should-plasma-gfap-guide-the-management-of-patients-with-traumatic-brain-injury-and-a-negative-ct-scan
#20
Fiona Lecky
No abstract text is available yet for this article.
August 23, 2019: Lancet Neurology
journal
journal
20188
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"